Hong Kong, 27 Oct 2021

Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) announces that the Group will deliver a keynote presentation entitled "Breakthrough Cancer Treatment: The Next Generation of Antibody Fragment Drug Conjugates (FDCs)" in Bio-Pharm 2021, held between November 4 and 5, 2021 in Guangzhou.

Time: Thursday, November 4, 2021, 10:40-11:10 am, Beijing time
Session: Antibody Drug Development and Engineering Conference
Speaker: Dr. Quinn Xue (Chief Scientific Officer, Essex Bio-Technology Limited)
Link: http://www.bio-pharmchina.com
 

~ End ~

 
About Anitbody Fragment  Drug Conjugates (FDCs)

Antibody Fragment Drug Conjugates (FDCs, also called immuno-conjugates) combine the pharmacological potency of highly cytotoxic drugs with the high specificity of an antibody against tumour-associated targets. FDCs comprises of much smaller antibody fragments (single-chain scFvs) than ‘whole’ antibody drug conjugates (ADCs). FDCs can be bio-engineered for multiple drug-molecule conjugation, leading to far higher loadings on a small fragment than has so far been achieved with whole monoclonal Antibodies (mAbs). FDCs have further demonstrated superior tumour penetration and rapid elimination from normal tissues, in vitro¹. With predicted sales of ADCs to be over $20 billion USD by 2028², FDCs as the next-generation of cancer therapeutics that is positioned to overcome many limitations of existing treatment options, will have exciting market potential.

About Bio-Pharm 2021

Held on November 4-5, 2021 in Guangzhou, sponsored by Shanghai Healife Group, the conference lasts for 2 days and will invite 100+ authoritative leaders and 1000+ industry experts to share the most cutting-edge technical information, interpret the latest industrial policies, and comprehensively link the multi-platform of industry, university, research and investment.
 
About Essex

Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 9,760 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
 
Reference